Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Nausea and Vomiting
Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV
Chemotherapy-induced nausea and vomiting is a common side effect of cancer treatments, and dexamethasone offers a clear advantage over placebo for protection against chemotherapy-induced emesis in both acute and delayed phases.
- Trial name
- NCT04437017
- Testing
- Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA
- Where
- China
- Volunteers
- 557 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Electroacupuncture, Olanzapine-contained Four-drug Antiemetic
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly…
- Conditions
- Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting
- Trial name
- NCT06200168
- Testing
- Electroacupuncture, Standard antiemetic treatment
- Where
- China
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Jiuda Zhao
Ovarian Neoplasm, Chemotherapeutic Toxicity
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Observational, clinical study. Intention to include 40 patients (20 patients treated with trabectedin and 20 with cisplatin hypersensitivity) The investigators investigate the role of trabectedin in combination with PLD and…
- Conditions
- Ovarian Neoplasm, Chemotherapeutic Toxicity, Chemotherapy Effect, Chemotherapy-induced Neutropenia
- Trial name
- TvsCH (NCT05512676)
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an…
- Trial name
- NCT02557035
- Testing
- Palonosetron, Dexamethasone
- Where
- 76 sites in Belarus, Bosnia and Herzegovina and 7 more
- Volunteers
- 441 people
- Sponsor
- Helsinn Healthcare SA
Multiple Myeloma, Autologous Stem Cell Transplantation
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy.
- Trial name
- FONDO-LOW (NCT06588413)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Augusta University
Breast Cancer, Lung Cancer
Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer
RATIONALE: Understanding how nausea or vomiting caused by chemotherapy effects a patient's treatment decisions may help doctors plan better cancer treatment and may help patients live more comfortably.
- Conditions
- Breast Cancer, Lung Cancer, Nausea and Vomiting
- Trial name
- NCT00416689
- Testing
- assessment of therapy complications, quality-of-life assessment
- Volunteers
- 99 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
Children aged 2-12 years scheduled to receive moderately or highly emetogenic chemotherapy were randomly assigned to arm-A (fosaprepitant) or arm-B (aprepitant).
- Trial name
- NCT04873284
- Testing
- fosaprepitant, aprepitant, Granisetron plus dexamethasone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Children's Medical Center
Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Trial name
- NCT01031953
- Testing
- fosaprepitant dimeglumine, systemic chemotherapy, survey administration
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- OHSU Knight Cancer Institute
Chemotherapy-induced Nausea and Vomiting (CINV)
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
- Trial name
- NCT00952341
- Testing
- aprepitant, dexamethasone, granisetron
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Vomiting, Nausea Post Chemotherapy
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced…
- Conditions
- Vomiting, Nausea Post Chemotherapy, Head Neck Cancer
- Trial name
- NCT03572829
- Testing
- Aprepitant
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese Academy of Medical Sciences
Chemotherapy-induced Nausea and Vomiting
Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting
Breast cancer patient receiving AC regimen chemotherapy (Doxorubicin + Cyclophosphamide) who has nausea score from 40/100 VAS or vomiting after the first or second cycle of chemotherapy is recruited.
- Trial name
- NCT02390648
- Testing
- Ginger
- Where
- Thailand
- Volunteers
- 34 people
- Sponsor
- Mahidol University
Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
The purpose of this study is to evaluate the efficacy and safety of fosaprepitant (MK-0517) plus ondansetron versus ondansetron alone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric participants…
- Trial name
- NCT02519842
- Testing
- Fosaprepitant, Ondansetron, Dexamethasone
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Gynecologic Cancer, Chemotherapy-induced Nausea and Vomiting
Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline
This study aims to investigate the adherence to the antiemesis NCCN guideline in Chinese patients of gynecologic malignancies, who are given chemotherapy treatment.
- Trial name
- NCT03740672
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Lei Li
Chemotherapy-induced Nausea and Vomiting, Colorectal Cancer
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic…
- Trial name
- NCT02909478
- Testing
- Aprepitant+Tropisetron, Dexamethasone+Tropisetron
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Pediatric Cancer
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
The purpose is to evaluate the effectiveness and safety of fosaprepitant plus ondansetron with dexamethasone or placebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE…
- Trial name
- NCT04508400
- Testing
- Fosaprepitant,ondansetron, dexamethasone
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-induced Nausea and Vomiting
Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to clarify whether distal-proximal point association is more effective than partial match point association by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .
- Trial name
- NCT02478047
- Testing
- only antiemetic (Ramosetron, Tropisetron and dexamethasone), Matching points ST36+CV12 plus antiemetic drug, Matching points PC6+CV12 plus antiemetic drug
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Tianjin University of Traditional Chinese Medicine
Nausea and Vomiting, Chemotherapy-Induced
Cyclophosphamide Drug Interaction Study In Cancer Patients
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
- Trial name
- NCT00334646
- Testing
- Oral GW679769, IV Cyclophosphamide 500-700mg/m2
- Where
- 5 sites in United States, New Zealand and 1 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Chemotherapy Induced Nausea and Vomiting
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Chemotherapy induced nausea and vomiting (CINV) is one of the few mostly observed distressing toxicity of cancer treatment. It can occur up to 90% in case of highly emetogenic chemotherapy use.
- Trial name
- Aprepitant (NCT01402024)
- Testing
- Aprepitant
- Where
- India
- Volunteers
- 96 people
- Sponsor
- All India Institute of Medical Sciences